Sun, Apr 20, 2014, 11:25 AM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

School Specialty Inc. Message Board

surftrader 3 posts  |  Last Activity: Mar 27, 2014 1:59 PM Member since: Oct 16, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • surftrader Mar 27, 2014 1:59 PM Flag

    The only similarity in Idera’s IMO-8400 and Celgene’s Otezla (apremilast) is that they share one indication: treatment of psoriasis. In addition to different route subcutaneous vs oral, the biggest difference is the mechanism of action. IMO-8400 is an antagonist of TLR7, TLR8, and TLR9, which blocks inflammatory cytokines without affecting constitutive cytokines. Otezla is an inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP). The prescribing information for Otezla states: “The specific mechanism(s) by which apremilast exerts its therapeutic action in psoriatic arthritis patients is not well defined.”

    I recommend learning about the multi-billion dollar industry of TNF inhibitors and compare how Idera’s approach to treating psoriasis and other inflammatory diseases differs. When you learn about biologic agents such as Enbrel and Humira, then see how Idera’s agents differ, you will realize why there is so much excitement about this company. After learning about the mechanisms of action of biologic agents and then compare to Otezla, you will have to conclude that there is no comparison because Celgene’s drug is by far inferior. Otezla will be limited to a niche population of patients that fail all other treatments, whereas Idera's drug candidates will be open to a significantly larger population of patients. I should also point out that Otezla is riskier in pregnant females (Class C), whereas biologic agents are Class B.

  • Reply to


    by crabhead Mar 13, 2014 9:36 AM surftrader Mar 13, 2014 11:17 PM Flag

    In order to test the strength of tendons, researchers stress the tendons by applying tension to them. The idea is to measure tensile strength as load is increased. Tendons that are able to handle greater tension before tearing are able to endure a heavier load before failing, therefore having a higher load-tofailure. I haven't read the pre-clinical study you refer to, but if what you wrote is accurate, one can conclude that PLX-PAD treated tendons are stronger than saline-treated tendons. That is good news for PLX-PAD treated patients and it is very good news for PSTI investors.

  • Reply to

    Comment to SA article. Must read.

    by garyflaks Feb 1, 2014 2:37 PM surftrader Feb 1, 2014 3:31 PM Flag

    Outstanding rebuttal! Thanks for setting the record straight. You offer unique insight that most are not privy to. The SA author should have contacted you before writing the hit piece on GALE.

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.